NO20052552L - Loselige Notch-baserte substrater for gamma-sekretase og fremgangsmater og blandinger for anvendelse av samme. - Google Patents

Loselige Notch-baserte substrater for gamma-sekretase og fremgangsmater og blandinger for anvendelse av samme.

Info

Publication number
NO20052552L
NO20052552L NO20052552A NO20052552A NO20052552L NO 20052552 L NO20052552 L NO 20052552L NO 20052552 A NO20052552 A NO 20052552A NO 20052552 A NO20052552 A NO 20052552A NO 20052552 L NO20052552 L NO 20052552L
Authority
NO
Norway
Prior art keywords
compositions
methods
gamma secretase
based substrates
soluble notch
Prior art date
Application number
NO20052552A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052552D0 (no
Inventor
Satish K Sharma
Kenneth Bruce Rank
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20052552D0 publication Critical patent/NO20052552D0/no
Publication of NO20052552L publication Critical patent/NO20052552L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
NO20052552A 2002-11-26 2005-05-26 Loselige Notch-baserte substrater for gamma-sekretase og fremgangsmater og blandinger for anvendelse av samme. NO20052552L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42920602P 2002-11-26 2002-11-26
PCT/IB2003/005233 WO2004048578A1 (en) 2002-11-26 2003-11-17 Soluble notch-based substrates for gamma secretase and methods and compositions for using same

Publications (2)

Publication Number Publication Date
NO20052552D0 NO20052552D0 (no) 2005-05-26
NO20052552L true NO20052552L (no) 2005-08-25

Family

ID=32393521

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052552A NO20052552L (no) 2002-11-26 2005-05-26 Loselige Notch-baserte substrater for gamma-sekretase og fremgangsmater og blandinger for anvendelse av samme.

Country Status (14)

Country Link
US (1) US20110098227A1 (de)
EP (1) EP1567647B1 (de)
JP (1) JP2006508653A (de)
KR (1) KR20050085177A (de)
CN (1) CN1717485A (de)
AT (1) ATE374824T1 (de)
AU (1) AU2003283619A1 (de)
CA (1) CA2505764A1 (de)
DE (1) DE60316718T2 (de)
ES (1) ES2293047T3 (de)
HR (1) HRP20050461A2 (de)
NO (1) NO20052552L (de)
RU (1) RU2005115973A (de)
WO (1) WO2004048578A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0518232D0 (en) * 2005-09-07 2005-10-19 Merck Sharp & Dohme New methods
US7910324B2 (en) 2007-06-08 2011-03-22 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the processing of EphA4 by γ-secretase
JP5580598B2 (ja) 2007-11-15 2014-08-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 γ−セクレターゼの新規基質EphA7を利用したスクリーニング方法
US9023767B2 (en) * 2009-05-07 2015-05-05 Memorial Sloan-Kettering Cancer Center γ-Secretase substrates and methods of use
CN103502466A (zh) * 2010-09-07 2014-01-08 斯隆-凯特林纪念癌症中心 用于γ-分泌酶测定的方法和组合物
JP6059017B2 (ja) 2010-12-17 2017-01-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法
JP5961608B2 (ja) 2011-04-25 2016-08-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257633A1 (de) * 2000-02-25 2002-11-20 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Presenilin defizient

Also Published As

Publication number Publication date
EP1567647A1 (de) 2005-08-31
NO20052552D0 (no) 2005-05-26
DE60316718T2 (de) 2008-01-24
JP2006508653A (ja) 2006-03-16
KR20050085177A (ko) 2005-08-29
US20110098227A1 (en) 2011-04-28
WO2004048578A1 (en) 2004-06-10
HRP20050461A2 (en) 2005-08-31
EP1567647B1 (de) 2007-10-03
DE60316718D1 (de) 2007-11-15
ATE374824T1 (de) 2007-10-15
RU2005115973A (ru) 2005-12-20
AU2003283619A1 (en) 2004-06-18
CA2505764A1 (en) 2004-06-10
CN1717485A (zh) 2006-01-04
ES2293047T3 (es) 2008-03-16

Similar Documents

Publication Publication Date Title
DE60325892D1 (de) Stellungs- und verwendungsverfahren
EP1229047A3 (de) IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung
PL374608A1 (en) Polypeptide formulation
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
NO20022095L (no) Heterocyklisk substituerte pyrazoloner
WO2019148026A8 (en) Il-22 fc fusion proteins and methods of use
NO20044221L (no) Nye forbindelser
ATE530672T1 (de) Rekombinante adenoviren mit affen-adenovirus proteinen und verwendung davon.
NO20076467L (no) Fusjonsproteiner som omfatter HIV-1 Tat- og/eller Nef-proteiner
EP3805248A3 (de) Prozess, um antikörper und therapeutische produkte zu konzentrieren
HUP0203567A2 (hu) APRIL-receptor (BCMA) és alkalmazásai
DE60332842D1 (de) Antagonisten des nogo-rezeptors
DK1675956T3 (da) Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression
DK1450847T3 (da) Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
NO962188D0 (no) Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav
WO2003070892A3 (en) Inhibitors of rgs proteins
NO20052552L (no) Loselige Notch-baserte substrater for gamma-sekretase og fremgangsmater og blandinger for anvendelse av samme.
ATE370159T1 (de) Streptavidin-bindungspeptid
AU2003903124A0 (en) Analogues of heteromeric proteins
PA8577701A1 (es) Polipeptido t20 pegilado
AU2003255355A1 (en) Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
DK1066328T3 (da) Kimært protein, der indeholder en intramolekylær chaperon-lignende sekvens, og dets anvendelse til insulinproduktion
DK1525188T3 (da) Hidtil ukendte derivater af 4,4-dithiobis-(3-aminobutan-1-sulfonater) og sammensætninger, der indeholder dem
WO2005042717A3 (en) Primate prokineticin and prokineticin receptor polypeptides, related compositions and methods
NO20055210D0 (no) Inhibitorproteiner av en protease og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application